Oral Contraceptives and Body Mass Index
Status: | Completed |
---|---|
Conditions: | Obesity Weight Loss |
Therapuetic Areas: | Endocrinology |
Healthy: | No |
Age Range: | 18 - 35 |
Updated: | 4/21/2016 |
Start Date: | September 2009 |
End Date: | December 2011 |
Improving Contraceptive Effectiveness in Obese Women
The main hypothesis for this study is that increased Body Mass Index (BMI) alters oral
contraceptive metabolism in a manner which results in decreased effectiveness in obese
women.
contraceptive metabolism in a manner which results in decreased effectiveness in obese
women.
This study is being conducted to understand how effective oral hormonal birth control (the
pill) is for women with high body mass index ("BMI" - the ratio of your height and weight
BMI"). Previous studies of birth control traditionally do not include women above a certain
BMI number, so safety and efficacy is not clearly understood in this population, yet the
pill is still widely used in women with high BMI.
Reproductive-aged, ovulatory women of obese (BMI >30 kg/m2), will be placed on oral
contraceptives for 2 months, then randomized into two intervention arms for an additional 2
months. At several key time points, synthetic steroid pharmacokinetics, gonadotropins (LH,
FSH) and ovarian hormone levels (estradiol, progesterone), ovarian follicular activity by
ultrasound monitoring, and cervical mucus testing will be monitored.
pill) is for women with high body mass index ("BMI" - the ratio of your height and weight
BMI"). Previous studies of birth control traditionally do not include women above a certain
BMI number, so safety and efficacy is not clearly understood in this population, yet the
pill is still widely used in women with high BMI.
Reproductive-aged, ovulatory women of obese (BMI >30 kg/m2), will be placed on oral
contraceptives for 2 months, then randomized into two intervention arms for an additional 2
months. At several key time points, synthetic steroid pharmacokinetics, gonadotropins (LH,
FSH) and ovarian hormone levels (estradiol, progesterone), ovarian follicular activity by
ultrasound monitoring, and cervical mucus testing will be monitored.
Inclusion Criteria:
- Age 18-35
- BMI > 30kg/m2
- Proof of a normal breast and pelvic exam within last 9 months
- Self reported normal menstrual periods (24-35 days)
- Good general health
- In the investigator's opinion, are subject's veins suitable the repeat blood draws
dictated by study protocol
- Single progesterone level during screening visit ≥ 3ng/mL
- Hematocrit ≥ 36%
Exclusion Criteria:
- Contradictions to COCs (history of deep vein thrombosis,myocardial infection,
uncontrolled hypertension, pulmonary embolus, diabetes with vascular changes, stroke,
migraines with neurologic changes, breast cancer, impaired liver function,
uncontrolled thyroid disease, hypersensitivity or allergy to birth control)
- Smoker (must smoke 0 cigarettes)
- Actively seeking/involved in a weight loss program
- Currently pregnant/seeking pregnancy in the next 6 months
- Currently breast-feeding
- Past or current diagnosis of polycystic ovarian disease
- Recent use of birth control (Depot medroxyprogesterone: 6 months, Progestin implants:
6 months, Oral contraceptives, patch or ring: 2 months, Hormone impregnated IUD: 6
months)
- Currently taking medication that interferes with COC's (Rifampin, Carbamazepine, St.
John's Wort)
We found this trial at
1
site
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials